Amgen Inc. (AMGN) Stock

Healthcare · Drug Manufacturers - General · Member of S&P 500, NASDAQ 100, Dow Jones

Amgen Inc. (AMGN) closed at USD 434.03 on 2026-10-15, a change of +52.9 % over the past year, with a market capitalization of USD 233.82B.

Amgen Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Amgen Inc. key figures

Previous close

USD 434.03 (2026-10-15)

1-year change

+52.9 %

Market cap

USD 233.82B

Enterprise value

USD 277.13B

P/E ratio (trailing)

26.86

P/E ratio (forward)

17.65

EPS (trailing)

16.10

EPS (forward)

24.50

PEG ratio

2.59

Price to book

20.00

Revenue growth

9.5 %

Earnings growth

64.9 %

Dividend per share (trailing)

9.80

Short ratio

4.45

Employees

31,500

Analyst consensus (third-party)

hold

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Amgen Inc. and compare it with other stocks.